Eef Schimmelpennink, LENZ Therapeutics CEO

LENZ plans NDA sub­mis­sion for pres­by­opia eye drops this year, looks to launch in 2025

LENZ Ther­a­peu­tics plans to seek FDA ap­proval for its in­ves­ti­ga­tion­al eye drops for pres­by­opia, set­ting up the drug to com­pete against Ab­b­Vie’s Vuity and Ora­sis Phar­ma­ceu­ti­cals’ Qlosi.

The bio­phar­ma on Wednes­day shared pos­i­tive Phase 3 da­ta for two for­mu­la­tions of the treat­ment, say­ing both met the study’s pri­ma­ry end­point, though it plans to pur­sue an NDA for the ver­sion that doesn’t in­clude bri­moni­dine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.